TFAP2C and urinary bladder carcinoma: While previous research focused on the downstream effects of YAP and β-catenin, this study elucidates a novel mechanism involving TFAP2C's role in regulating these pathways, representing a significant progression in understanding cisplatin resistance in bladder cancer.